26.80 -0.13 (-0.48%)
After hours: 4:35PM EDT
|Bid||26.50 x 800|
|Ask||26.87 x 2900|
|Day's Range||25.45 - 27.25|
|52 Week Range||2.14 - 27.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.36|
Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its second quarter 2018 results after the financial markets close on Monday, July 30, 2018.
LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. WallStEquities.com takes a close look at four Medical Instruments and Supplies stocks, particularly, Tandem Diabetes Care Inc. (NASDAQ: TNDM), The Cooper Cos. Inc. (NYSE: COO), TransEnterix Inc. (NYSE American: TRXC), and Waters Corp. (NYSE: WAT).
On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump. On June 26, Tandem stock was trading ~1,000% higher than the 52-week low of $2.14 it reached on February 9.
In fiscal 2018, Tandem Diabetes Care (TNDM) expects sales at the mid-to-upper end of its $132 million–$140 million guidance. This confident sales outlook comes despite the company discontinuing its t:flex insulin pump by the end of fiscal Q2 2018. The company registered sales of $102.6 million in fiscal 2017 and $27.3 million in Q1 2018, ahead of analysts’ estimates.
Tandem Diabetes Care Rises 21%: Could It See More Upside? Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017. At the time, the move largely benefited Medtronic (MDT), the largest player in the insulin pump market.
After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump. Following the news, Oppenheimer analyst Steven Lichtman shared his views on Tandem, writing, “Approval timing is in line, though compatibility with Dexcom’s new G6 sensor in the initial approval is upside to expectations; TNDM had assumed a staggered approval with G5 compatibility first, potentially followed shortly thereafter by iCGM designation/G6 compatibility.” He added, “Earlier G6 approval bodes well for the initial launch later this summer. ...
Apart from selling insulin pumps, Tandem Diabetes Care (TNDM) also sells disposable products that are used together with pumps and are replaced every few days. These include cartridges and infusion sets. Tandem’s products on the market include t:slim, t:flex, and t:slim G4. In October 2016, Tandem commercialized t:slim X2 and discontinued t:slim. At present, the t:slim X2 platform represents almost the entire new pump shipments of the company. Tandem plans to discontinue sales of t:flex pumps from Q3 2018.
Tandem Diabetes Care’s (TNDM) t:slim X2 with control IQ is its second generation AID system that is expected to integrate the t:slim X2 pump with the technology Tandem licensed from TypeZero Technologies and Dexcom’s (DXCM) G6 sensor. In its international diabetes closed loop (or IDCL) trial, Tandem is working with TypeZero and Dexcom on the integration of their technologies. Further, Tandem plans to use these results in a premarket approval (or PMA) submission to the U.S. Food and Drug Administration (or FDA).
Due to the decrease in SG&A expenses, the total operating expenses of Tandem Diabetes Care decreased from $28.0 million in Q1 2017 to $26.9 million in Q1 2018, which further helped the company in reducing its operating loss to $15.5 million in Q1 2018 as compared with an operating loss of $21.2 million in Q1 2017.
The company earns revenues from the sale of insulin pumps, infusion sets, and cartridges. In comparison, in Q1 2017, infusion set sales generated $3.4 million and cartridge sales generated $2.9 million.
In Q1 2018, Tandem Diabetes Care (TNDM) used $12.3 million in operating activities as compared with $20.8 million in Q1 2017. This decrease was attributable to a decline in the net loss after adjusting for non-cash expenses and net changes in working capital.
Tandem Diabetes Care (TNDM) is a medical devices manufacturer. Its products are targeted at people with insulin-dependent diabetes. Five of the total six analysts covering Tandem Diabetes Care in June have given the stock a “buy” or a higher rating, while one analyst has given it a “hold” rating.
While small-cap stocks, such as Tandem Diabetes Care Inc (NASDAQ:TNDM) with its market cap of US$1.18b, are popular for their explosive growth, investors should also be aware of their balanceRead More...
If you’ve been with Tandem Diabetes Care (NASDAQ:TNDM) since in the early innings of its massive rally in April, you really enjoyed the over 13 percent rally on Friday. The main cause was the FDA approval of Tandem’s t:slim X2 Insulin Pump with Basal-IQ. On June 21, the FDA approved Senseonics Holdings’ (NYSEAMERICAN:SENS) Eversense Continuous Glucose Monitoring (“CGM”) System.
Late Thursday, Tandem Diabetes Care Inc (NASDAQ: TNDM ) announced FDA approval of its t:slim X2 insulin pump with Basal-IQ for Type 1 diabetes patients, which is planned for an August launch. With the ...
Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology yesterday after the market closed. Today, Medtronic (MDT) and Insulet (PODD), other major players in the insulin pump market, opened ~0.42% and ~0.74% higher, respectively, than yesterday’s closing prices. Tandem Diabetes Care’s recently approved t:slim X2 insulin pump features Basal IQ technology, which helps reduce the frequency and duration of the events characterized by low glucose levels with a “predictive low glucose suspend” feature.
The medical device maker announced Thursday the FDA approved its t:slim X2 Insulin pump with Basal-IQ technology. Tandem Diabetes expects to make the t:slim X2 pump with Basal-IQ technology available in the U.S. in August.
Check out the companies making headlines after the bell: Shares of Red Hat RHT plummeted more than 11 percent in extended-hours trading, after the company reported better than expected first quarter earnings and revenue , but reported weak guidance.
Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.S. Food and Drug Administration (FDA) approval of the t:slim X2™ Insulin Pump with Basal-IQ™ technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia). This is the first automated insulin delivery system approved for use by children as young as 6 years old, and the first insulin pump designated as compatible with integrated continuous glucose monitoring (iCGM) devices.